查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947972

按分子類型、適應症、最終用戶和通路分類的聚乙二醇己烯酸注射市場，全球預測，2026-2032年

Pegcetacoplan Injection Market by Molecular Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，pegcetacoplan 注射劑市值將達到 5.3342 億美元，到 2026 年將成長至 5.6428 億美元，到 2032 年將達到 9.0351 億美元，複合年成長率為 7.81%。

關鍵市場統計數據
基準年 2025 5.3342億美元
預計年份：2026年 5.6428億美元
預測年份 2032 9.0351億美元
複合年成長率 (%) 7.81%

基於實證醫學的培塞他考普蘭注射液研究方法強調了臨床意義、給藥挑戰以及影響其應用趨勢的支付方考量。

Pegcetacoplan 是一種新型治療方法，針對補體通路，透過注射給藥，用於治療退化性眼科疾病和補體依賴性溶血性疾病等臨床適應症。作為一種基於機制的干涉措施，它引發了關於補體抑制、給藥方案以及不同治療方法比較等方面的全新臨床討論。臨床實踐、支付系統和生產製造等各方相關人員都在努力適應生物目標複雜的給藥要求和微妙的報銷環境。

監管核准、物流創新和支付方結果導向正在重塑注射型補充療法和醫療保健服務的未來。

在監管部門的核准、臨床計畫的拓展以及多種給藥模式的融合推動下，標靶補體注射療法的治療格局已從理論設想走向實際應用。創新的監管里程碑驗證了臨床方法，並推動了新的臨床試驗和仿單標示外研究，以探索更廣泛的適應症和最佳化給藥策略。同時，在醫院、專科診所和家庭環境中生物製藥的經驗也揭示了營運瓶頸以及以患者為中心的服務設計的新機會。

在不斷變化的貿易環境中，應對日益成長的關稅風險和供應鏈複雜性，以維持注射用生物製藥的可及性和財務永續性。

美國2025年實施的貿易政策調整和關稅措施，為注射用生物製藥的生產商、供應商和支付者引入了新的戰略變數。某些藥品原料和成品生物製劑進口關稅的提高，促使企業更加重視供應鏈韌性、服務成本會計以及區域製造地。以往致力於實現最低落地成本的企業，如今需要在不斷增加的關稅風險和跨境依賴帶來的營運風險之間尋求平衡。

深度細分分析揭示了適應症、劑量、臨床環境、通路和支付機制如何共同驅動現實世界的應用趨勢。

細分市場分析揭示了臨床適應症、製劑強度、給藥途徑、分銷方式和支付結構如何相互交織，共同塑造了培塞他考普蘭注射液的用藥模式和治療路徑。退化性眼科疾病（如地圖狀萎縮）與全身性補體介導疾病（如陣發性睡眠性血尿症）之間的臨床差異，不僅影響給藥方案和監測需求，也影響參與治療的醫療服務網路和專科服務。這些針對特定適應症的考量決定了最佳的治療環境以及病患監測和長期追蹤的模式。

區域比較分析，重點在於法規結構、支付模式和交付基礎設施對全球主要地區採用率的影響

區域趨勢差異顯著，法規環境、醫療基礎設施成熟度和支付體系的差異都會影響注射療法的採用和普及。美洲地區擁有強大的臨床專業知識基礎、多元化的支付方以及高度發展的專科藥房網路，一旦獲得監管核准和報銷，即可迅速推廣應用程式。然而，私營和公共支付方之間的碎片化可能會延長患者獲得治療的時間，並需要強力的價值溝通。

決定誰能成功將臨床創新轉化為永續的商業性管道和患者支持的策略競爭動態和合作夥伴生態系統至關重要。

注射型輔助療法的競爭格局呈現出多元化的策略定位，涵蓋藥物研發公司、專科製藥公司、契約製造組織以及專業的分銷和病患支援服務供應商。藥物研發公司強調整合式醫療模式，包括臨床差異化、擴展適應症、依從性支持計畫以及真實世界證據的生成，以支持健保報銷談判。這些項目通常將臨床結果數據與患者支持服務相結合，以展現長期價值並減少因給藥複雜性而造成的障礙。

透過結合臨床證據、穩健的生產製造和支付方參與的協作策略，實現患者永續獲得注射療法。

產業領導者應優先考慮整合臨床證據規劃、供應鏈韌性和支付方合作的方法，以加速注射輔助療法的推廣應用。制定全面的證據藍圖，包括註冊登記、可操作性研究和病患報告結果，將加強報銷責任制，並支持與公共和私人支付方簽訂差異化合約。同時，投資多元化的生產和填充能力，特別是地域分散的生產能力，將降低受關稅波動和運輸中斷的影響。

一項嚴謹的混合方法研究結合了關鍵相關人員訪談和系統的二手文獻綜述，旨在得出檢驗且可操作的研究結果。

我們的研究途徑結合了有針對性的初步研究和嚴謹的二次研究，旨在整合與注射輔助療法相關的臨床、監管、營運和支付方觀點。初步研究包括對臨床醫生、專科藥劑師和供應鏈專家進行結構化訪談，以了解實際應用、實施障礙和新興服務模式。此外，我們也諮詢了報銷專家和醫院採購負責人，以了解支付方的優先事項和合約動態，從而補充了這些定性見解。

結合臨床應用前景和營運準備情況，為不同醫療機構中的注射型補體療法創建永續的患者獲取途徑。

注射用pegcetacoplan代表了補體標靶治療領域的一項突破性進展，它既具有臨床應用前景，也因其操作複雜性而需要製造商、醫療服務提供者和支付方的協調配合。要成功地將治療創新轉化為患者獲益，需要製定一項整合循證醫學證據、靈活給藥途徑、穩健生產以及與支付方價值共用的策略。積極設計適應性強的護理模式並投資於真實世界數據收集的相關人員，將更有利於證明治療效果並確保患者的持續可及性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依分子類型分類的聚乙二醇化卡波羅注射市場

  • 聚乙二醇化合成胜肽
  • 雙重作用機制
  • 近端補體抑制譜

9. 依適應症分類的聚乙二醇己泊洛蘭注射劑市場

  • 地圖狀萎縮
  • 陣發性睡眠性血尿症

第10章 以最終用戶分類的聚乙二醇化卡波羅注射液市場

  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章 聚乙二醇化己酮注射液市場（依通路分類）

  • 線上
  • 離線

第12章 聚乙二醇化卡波羅注射液市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 聚乙二醇化卡波羅注射液市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國培塞他卡泊羅蘭注射市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國培塞他卡泊羅蘭注射市場

第16章 中國聚乙二醇化己酮類固醇注射市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-4F7A6D4FB6B6

The Pegcetacoplan Injection Market was valued at USD 533.42 million in 2025 and is projected to grow to USD 564.28 million in 2026, with a CAGR of 7.81%, reaching USD 903.51 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 533.42 million
Estimated Year [2026] USD 564.28 million
Forecast Year [2032] USD 903.51 million
CAGR (%) 7.81%

An evidence-driven orientation to pegcetacoplan injection that frames clinical relevance, administration challenges, and payer considerations shaping adoption dynamics

Pegcetacoplan represents a novel therapeutic modality targeting the complement pathway and delivered by injection for clinical indications such as degenerative ocular disease and complement-mediated hemolytic disorders. As a mechanism-driven intervention, it has introduced new clinical conversation around complement inhibition, administration paradigms, and cross-therapy comparisons. Stakeholders across clinical practice, payer systems, and manufacturing are adjusting to a landscape where targeted biologics intersect complex administration requirements and nuanced reimbursement environments.

Clinicians are engaging with evolving safety and efficacy datasets while health systems evaluate operational readiness for repeated injectable therapies that may span ambulatory, specialty clinic, and home administration settings. Payers are increasingly focused on value-based outcomes and real-world evidence to guide coverage decisions, while manufacturers are optimizing supply chains, labeling strategies, and patient support programs to reduce friction in therapy adoption. In this environment, clarity about clinical positioning, administration pathways, and support infrastructure is essential to convert therapeutic potential into sustainable patient access and commercial viability.

This introduction establishes the therapeutic, operational, and payer context that underpins the deeper insights and recommendations presented in the following sections, offering readers a concise but comprehensive orientation to the issues that will shape strategic choices around pegcetacoplan injection.

How regulatory validation, logistics innovation, and payer emphasis on outcomes are reshaping the future of injectable complement therapies and care delivery

The treatment landscape for complement-targeted injections has shifted from theoretical promise to pragmatic implementation as regulatory authorizations, expanding clinical programs, and divergent care delivery models converge. Innovative regulatory milestones have validated the clinical approach, prompting new clinical trials and off-label research that explore broader indications and optimized dosing strategies. Simultaneously, the experience of delivering a biologic injection across hospital, specialty clinic, and home settings has revealed operational bottlenecks and new opportunities for patient-centric service design.

Technological advances in cold-chain logistics, on-demand specialty pharmacy distribution, and digital adherence tools are reshaping how injectable biologics are supported across the continuum of care. Payer strategies have evolved to emphasize outcomes and cost-effectiveness, which in turn has elevated the importance of real-world evidence generation and patient-reported outcomes in commercialization plans. The confluence of these shifts is prompting manufacturers and providers to reimagine contracting, care pathways, and patient support ecosystems to accelerate uptake while protecting margins and maintaining high standards of safety and adherence.

Taken together, these transformative shifts create a dynamic environment in which agility, evidence generation, and integrated service models will determine which clinical and commercial strategies succeed in driving meaningful patient access.

Navigating increased tariff exposure and supply chain complexity to maintain access and financial sustainability for injectable biologics in a changing trade environment

Trade policy adjustments and tariff measures introduced in the United States in 2025 have introduced an additional strategic variable for manufacturers, suppliers, and payers involved with injectable biologics. Rising import duties on certain pharmaceutical components and finished biologic products have increased enterprise attention on supply chain resilience, cost-to-serve calculations, and regional manufacturing footprints. Organizations that historically optimized for lowest landed cost now balance that objective against elevated tariff exposure and the operational risks of cross-border dependencies.

Consequently, manufacturers are accelerating diversification of suppliers, investing in localized fill/finish capacity, and renegotiating supplier contracts to mitigate tariff pass-through to patients and health systems. Payers and procurement teams are scrutinizing total treatment costs, including indirect supply-chain surcharges, and are increasingly seeking contractual protections such as price adjustment clauses tied to tariff changes. These developments are influencing product lifecycle plans and commercial contracting, encouraging strategic vertical integration or partner selection that reduces customs and duty risk.

The cumulative effect of these tariff-driven dynamics is a renewed focus on strategic sourcing, contingency planning, and transparent communication among manufacturers, distributors, and payers to preserve access while protecting financial sustainability in the face of evolving trade policy.

Deep segmentation intelligence revealing how indication, dosage strengths, care settings, distribution channels, and payment mechanisms collectively drive real-world adoption

Segmentation insights reveal how clinical indication, formulation strength, administration setting, distribution approach, and payment structures intersect to shape adoption patterns and care pathways for pegcetacoplan injection. Clinical differentiation between degenerative ocular disease such as geographic atrophy and systemic complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria informs not only dosing regimens and monitoring needs but also the provider networks and specialty services engaged in treatment delivery. These indication-specific considerations determine which care settings are most appropriate and how patient monitoring and long-term follow-up are structured.

Product configuration, including higher-concentration and lower-concentration strengths such as 1080 Mg and 180 Mg, creates opportunities to match dosing convenience with safety profiles, impacting both patient adherence and administration frequency. End-user diversity, spanning home healthcare, hospitals, and specialty clinics, necessitates flexible patient support programs and training modules that ensure safe, effective handling across settings. Likewise, distribution choices among hospital pharmacy, online pharmacy, and retail pharmacy channels shape time-to-treatment, cold-chain management practices, and companion services like adherence packaging or counseling.

Finally, payment ecosystems composed of government reimbursement, out-of-pocket arrangements, and private insurance determine financial access pathways and influence stakeholder conversations about value, copayment support, and prior authorization workflows. Integrating these segmentation dimensions into development and commercialization plans helps align product design, service delivery, and contracting with the practical realities clinicians and patients face.

Comparative regional intelligence showing how regulatory frameworks, payer models, and delivery infrastructure influence adoption across major global territories

Regional dynamics vary markedly, with distinct regulatory environments, healthcare infrastructure maturity, and payer systems shaping how injectable therapies are introduced and scaled. The Americas feature concentrated centers of clinical expertise, diverse payers, and well-developed specialty pharmacy networks that can support rapid adoption where regulatory clearance and reimbursement align; however, fragmentation across private and public payers can lengthen access timelines and necessitate robust value communication.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and reimbursement mechanisms, where centralized approvals can be complemented by national-level HTA assessments that drive diverse market entry strategies. In this region, centralized procurement and price negotiation mechanisms may create both opportunities for scale and constraints on pricing flexibility, whereas differences in clinic capacity and specialty services influence where injections are delivered.

Asia-Pacific spans highly advanced healthcare systems with strong private-sector specialty networks alongside emerging markets where infrastructure and reimbursement maturity vary. In this region, local manufacturing partnerships, regional regulatory harmonization, and innovative financing arrangements often determine the speed and breadth of access. Across all regions, tailoring go-to-market tactics to regulatory timelines, distribution capabilities, and payer expectations is essential to optimize clinical reach and patient outcomes.

Strategic competitive dynamics and partner ecosystems that determine who successfully translates clinical innovation into sustainable commercial access and patient support

Competitive dynamics for injectable complement therapies are characterized by a range of strategic postures that include originator developers, specialty pharma players, contract manufacturing organizations, and service providers focused on distribution and patient support. Innovator companies emphasize clinical differentiation, label expansion, and integrated care models that include adherence programs and real-world evidence generation to support reimbursement negotiations. These programs often couple clinical outcomes data with patient support services to demonstrate longitudinal value and reduce barriers tied to administration complexity.

Manufacturing and supply partners are increasingly important as firms seek to secure fill/finish capacity, cold-chain expertise, and scalable packaging solutions that meet both clinical and regulatory requirements. Contract manufacturing organizations that can provide localized production and rapid scale-up have become strategic allies in minimizing tariff and logistics exposure. Distribution and specialty pharmacy networks that offer temperature-controlled delivery, clinician education, and patient onboarding services are similarly central to successful product rollouts.

New market entrants and specialty competitors will focus on differentiated service models and lifecycle strategies, while established developers must protect clinical credibility and payer relationships through consistent evidence generation and transparent outcomes reporting. Strategic collaborations across clinical, manufacturing, and distribution partners will continue to shape competitive positioning and access trajectories.

Actionable strategies for aligning clinical evidence, resilient manufacturing, and payer engagement to deliver sustainable patient access for injectable therapies

Industry leaders should prioritize an integrated approach that aligns clinical evidence plans, supply chain resilience, and payer engagement to accelerate adoption of injectable complement therapies. Developing a comprehensive evidence generation roadmap that includes registries, pragmatic studies, and patient-reported outcomes will strengthen reimbursement narratives and support differentiated contracting with both public and private payers. Concurrently, investing in diversified manufacturing and fill/finish arrangements-particularly geographically distributed capacity-will reduce exposure to tariff volatility and transport disruptions.

Operationally, leaders should design flexible care delivery models that enable safe administration across hospitals, specialty clinics, and home healthcare settings, supported by robust training programs for clinicians and caregivers. Distribution strategies must leverage specialty pharmacy partnerships and digital platforms to ensure timely, temperature-controlled delivery while offering patient-centric services that minimize adherence friction. On the commercial front, negotiate outcome-based arrangements where feasible and develop transparent pricing constructs and copay assistance frameworks that address affordability concerns.

Finally, cultivate strategic collaborations with healthcare systems, payers, and patient advocacy groups to co-create care pathways and education initiatives that improve uptake while managing total cost of care. These coordinated actions will position organizations to translate clinical promise into durable, patient-centered access.

A rigorous mixed-methods research framework combining primary stakeholder interviews and systematic secondary review to generate validated, actionable insights

The research approach combined targeted primary inquiry with rigorous secondary analysis to synthesize clinical, regulatory, operational, and payer perspectives relevant to injectable complement therapies. Primary research included structured interviews with clinicians, specialty pharmacists, and supply-chain experts to capture real-world administration practices, barriers to adoption, and emerging service models. These qualitative insights were complemented by consultations with reimbursement specialists and hospital procurement officials to understand payer priorities and contracting dynamics.

Secondary research encompassed a systematic review of peer-reviewed literature, regulatory approvals, clinical trial registries, and policy announcements to ensure factual alignment with the latest publicly available evidence. Cross-validation occurred through triangulation of primary interview findings with regulatory filings and published safety and efficacy data. Scenario-based analysis was applied to test the resilience of supply-chain and commercial strategies under differing tariff, distribution, and reimbursement assumptions.

Throughout the methodology, emphasis was placed on transparency of sources, corroboration of stakeholder claims, and the practical implications of findings for commercial, clinical, and operational decision-making. This mixed-methods design ensured a balanced, actionable view of the complex variables affecting injectable therapy adoption.

Converging clinical promise and operational readiness to create sustainable patient access pathways for injectable complement therapies in diverse healthcare environments

Pegcetacoplan injection represents a pivotal development in complement-targeted therapy, bringing both clinical promise and operational complexity that require coordinated responses from manufacturers, providers, and payers. Successful translation of therapeutic innovation into patient benefit depends on integrated strategies that address evidence generation, flexible administration pathways, resilient manufacturing, and payer-aligned value communication. Stakeholders that proactively design adaptable care models and invest in real-world data capture will be better positioned to demonstrate outcomes and secure durable access.

Trade policy dynamics and distribution channel evolution add layers of strategic consideration that can materially influence cost structures and time-to-treatment, emphasizing the need for contingency planning and regional manufacturing partnerships. Segmentation insights underscore that indication-specific needs, dosing configurations, care settings, distribution approaches, and payment mechanisms all interact to determine how therapies are adopted in practice. A holistic approach that aligns these dimensions with clinical goals and patient needs is essential for realizing long-term impact.

In sum, a coordinated emphasis on evidence, operational readiness, and payer engagement will be central to converting the clinical potential of injectable complement therapies into consistent, equitable access for patients across varied healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pegcetacoplan Injection Market, by Molecular Type

  • 8.1. Pegylated Synthetic Peptide
  • 8.2. Dual Mechanism of Action
  • 8.3. Proximal Complement Inhibition Profile

9. Pegcetacoplan Injection Market, by Indication

  • 9.1. Geographic Atrophy
  • 9.2. Paroxysmal Nocturnal Hemoglobinuria

10. Pegcetacoplan Injection Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospital
  • 10.3. Specialty Clinic

11. Pegcetacoplan Injection Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Pegcetacoplan Injection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pegcetacoplan Injection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pegcetacoplan Injection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pegcetacoplan Injection Market

16. China Pegcetacoplan Injection Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Apellis Pharmaceuticals Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. GlaxoSmithKline plc
  • 17.10. Johnson & Johnson
  • 17.11. Merck & Co. Inc.
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. Roche Holding AG
  • 17.15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEGCETACOPLAN INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEGCETACOPLAN INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PEGYLATED SYNTHETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PEGYLATED SYNTHETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PEGYLATED SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DUAL MECHANISM OF ACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DUAL MECHANISM OF ACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DUAL MECHANISM OF ACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITION PROFILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITION PROFILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITION PROFILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GCC PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. G7 PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NATO PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEGCETACOPLAN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, BY MOLECULAR TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA PEGCETACOPLAN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)